Search results
Your search for DEKAS Plus returned no results
Showing 31 to 45 of 168 results for delay plus
Showing 31 to 45 of 168 results for delay plus
Evidence-based recommendations on ciclosporin (Ikervis) for dry eye disease in adults that has not improved despite treatment with artificial tears.
Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.
This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.
Evidence-based recommendations on ribociclib (Kisqali) with an aromatase inhibitor for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.
Show all sections
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)
Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy.
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated unresectable malignant pleural mesothelioma in adults.
This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.
Evidence-based recommendations on bevacizumab (Avastin), with paclitaxel and carboplatin, for treating advanced ovarian cancer in adults.
Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over.
Obeticholic acid for treating primary biliary cholangitis (TA443)
Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis in adults.
Specialist neonatal respiratory care for babies born preterm (NG124)
This guideline covers specific aspects of respiratory support (for example, oxygen supplementation, assisted ventilation, treatment of some respiratory disorders, and aspects of monitoring) for preterm babies in hospital.
This guideline covers safe midwifery staffing in all maternity settings, including at home, in the community, in day assessment units, in obstetric units, and in units led by midwives (both alongside hospitals and free-standing). It aims to improve maternity care by giving advice on monitoring staffing levels and actions to take if there are not enough midwives to meet the needs of women and babies in the service.
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)
Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (also known as Viekirax) with or without dasabuvir (also known as Exviera) for adults with some types (called genotypes) of chronic hepatitis C.
Urinary tract infection (catheter-associated): antimicrobial prescribing (NG113)
This guideline sets out an antimicrobial prescribing strategy for catheter-associated urinary tract infection in children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.
Constipation in children and young people: diagnosis and management (CG99)
This guideline covers diagnosing and managing constipation in children and young people up to 18. It provides strategies to support the early identification and timely, effective treatment of constipation which will help improve outcomes for patients. It does not cover constipation caused by a specific condition.